Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 95

1.

Growth and endocrine disorders in thalassemia: The international network on endocrine complications in thalassemia (I-CET) position statement and guidelines.

De Sanctis V, Soliman AT, Elsedfy H, Skordis N, Kattamis C, Angastiniotis M, Karimi M, Yassin MA, El Awwa A, Stoeva I, Raiola G, Galati MC, Bedair EM, Fiscina B, El Kholy M.

Indian J Endocrinol Metab. 2013 Jan;17(1):8-18. doi: 10.4103/2230-8210.107808.

PMID:
23776848
[PubMed]
Free PMC Article
2.

International network on endocrine complications in thalassaemia (I-CET): an opportunity to grow.

De Sanctis V, Soliman AT, Angastiniotis M, Eleftheriou A, Kattamis Ch, Karimi M, El Kholy M, Elsedfy H, Yassin MA, El Awwa A, Stoeva I, Skordis N, Raiola G, Fiscina B.

Georgian Med News. 2012 Apr;(205):52-7.

PMID:
22665732
[PubMed - indexed for MEDLINE]
3.

Thalassemia.

Cohen AR, Galanello R, Pennell DJ, Cunningham MJ, Vichinsky E.

Hematology Am Soc Hematol Educ Program. 2004:14-34. Review.

PMID:
15561674
[PubMed - indexed for MEDLINE]
Free Article
4.

Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF).

De Sanctis V, Eleftheriou A, Malaventura C; Thalassaemia International Federation Study Group on Growth and Endocrine Complications in Thalassaemia.

Pediatr Endocrinol Rev. 2004 Dec;2 Suppl 2:249-55.

PMID:
16462705
[PubMed - indexed for MEDLINE]
5.

Growth and puberty and its management in thalassaemia.

De Sanctis V.

Horm Res. 2002;58 Suppl 1:72-9. Review.

PMID:
12373018
[PubMed - indexed for MEDLINE]
6.

Prevalence of growth and puberty failure with respect to growth hormone and gonadotropins secretion in beta-thalassemia major.

Moayeri H, Oloomi Z.

Arch Iran Med. 2006 Oct;9(4):329-34.

PMID:
17061604
[PubMed - indexed for MEDLINE]
7.
8.

Beta-thalassemia.

Galanello R, Origa R.

Orphanet J Rare Dis. 2010 May 21;5:11. doi: 10.1186/1750-1172-5-11. Review.

PMID:
20492708
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Endocrine complications in patients with Thalassaemia Major.

Toumba M, Sergis A, Kanaris C, Skordis N.

Pediatr Endocrinol Rev. 2007 Dec;5(2):642-8. Review.

PMID:
18084158
[PubMed - indexed for MEDLINE]
10.

Growth and puberty in thalassemia major.

Raiola G, Galati MC, De Sanctis V, Caruso Nicoletti M, Pintor C, De Simone M, Arcuri VM, Anastasi S.

J Pediatr Endocrinol Metab. 2003 Mar;16 Suppl 2:259-66. Review.

PMID:
12729401
[PubMed - indexed for MEDLINE]
12.

Cardiac function and iron chelation in thalassemia major and intermedia: a review of the underlying pathophysiology and approach to chelation management.

Aessopos A, Berdoukas V.

Mediterr J Hematol Infect Dis. 2009 Jul 18;1(1):e2009002. doi: 10.4084/MJHID.2009.002.

PMID:
21415984
[PubMed]
Free PMC Article
13.

Understanding iron overload: screening, monitoring, and caring for patients with transfusion-dependent anemias.

Ault P, Jones K.

Clin J Oncol Nurs. 2009 Oct;13(5):511-7. doi: 10.1188/09.CJON.511-517.

PMID:
19793708
[PubMed - indexed for MEDLINE]
14.

Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications.

Farmaki K, Tzoumari I, Pappa C.

Blood Cells Mol Dis. 2011 Jun 15;47(1):33-40. doi: 10.1016/j.bcmd.2011.03.007. Epub 2011 Apr 29.

PMID:
21531154
[PubMed - indexed for MEDLINE]
15.

Endocrine complications in transfusion dependent thalassaemia in Penang Hospital.

Ong CK, Lim SL, Tan WC, Ong EE, Goh AS.

Med J Malaysia. 2008 Jun;63(2):109-12.

PMID:
18942294
[PubMed - indexed for MEDLINE]
Free Article
16.

Mild subclinical hypothyroidism in thalassaemia major: prevalence, multigated radionuclide test, clinical and laboratory long-term follow-up study.

De Sanctis V, De Sanctis E, Ricchieri P, Gubellini E, Gilli G, Gamberini MR.

Pediatr Endocrinol Rev. 2008 Oct;6 Suppl 1:174-80.

PMID:
19337174
[PubMed - indexed for MEDLINE]
17.

Treatment of iron overload in thalassemia.

Cianciulli P.

Pediatr Endocrinol Rev. 2008 Oct;6 Suppl 1:208-13. Review.

PMID:
19337180
[PubMed - indexed for MEDLINE]
18.

Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.

Delea TE, Edelsberg J, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD.

Transfusion. 2007 Oct;47(10):1919-29. Review.

PMID:
17880620
[PubMed - indexed for MEDLINE]
19.

Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.

Daar S, Pathare AV.

Ann Hematol. 2006 May;85(5):315-9. Epub 2006 Feb 1.

PMID:
16450126
[PubMed - indexed for MEDLINE]
20.

[Evaluation of heart and liver iron deposition status in patients with β- thalassemia intermedia and major with MRI T2* technique].

Li CG, Liu SX, Mai HR, Wang Y, Wen FQ, Liu RY, Zhang XH, Chu WC, Au WY.

Zhongguo Dang Dai Er Ke Za Zhi. 2012 Feb;14(2):110-3. Chinese.

PMID:
22357467
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk